ArticleAntibiotics (Basel, Switzerland)2022
Epidemiological, Clinical and Microbiological Characteristics of Patients with Bloodstream Infections Due to Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Clinical and molecular characteristics, antibiotic susceptibility, risk factors and predictors of mortality in carbapenem-resistant klebsiella pneumoniae bloodstream infections in Southern Sichuan, China: a 5-year multicenter study.Frontiers in cellular and infection microbiology · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Article
- Molecular epidemiology and clinical characteristics of carbapenem-resistantMicrobiology spectrum · 2025Article
- Carbapenem-Resistant Gram-Negative Bacteria in Hospitalized Patients: A Five-Year Surveillance in Italy.Infectious disease reports · 2025Article
- Detection of KPC-Producing Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Article
- Dynamic cytokine profiles of bloodstream infection caused by Klebsiella pneumoniae in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Epidemiological Characteristics and Antimicrobial Resistance Changes of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Prompt and Appropriate Antimicrobial Therapy Improves Outcomes of NDM-Producing and KPC-ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the present study, our aim was to evaluate the clinical and microbiological characteristics of a cohort of patients with bloodstream infections (BSI) due to Carbapenem-Resistant Enterobacteriaceae (CRE) and investigate the independent predictors of mortality.
methodsAll episodes of carbapenem-resistant
resultsDuring the study period, a total of 154 consecutive non-repeated CRE BSI, all due to CRKp, were reported. The most frequently identified genes were KPC in 108 cases (70.1%), followed by metallo-betalactamases (MBL) (16.2%), and OXA-48 (2.6%); in 17 isolates (11%) no carbapenemase was detected. The overall mortality at 90 days was 41.9%. Using a log-rank test, patients without risk factors for CRE infections showed a significantly lower cumulative mortality (
conclusionsThe study reported a non-negligible prevalence of MBL-producing organisms among CRKp isolated from blood cultures in our region. This data highlights the importance of molecular characterization of all clinical isolates of carbapenem-resistant organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.